Urban brides and grooms in India are using injectable GLP-1 weight-loss drugs to prepare for their wedding days [1, 2].
This trend highlights the intense cultural pressure on couples to achieve a specific physical aesthetic for wedding ceremonies. The shift toward pharmaceutical interventions for cosmetic goals raises concerns about the off-label use of medications intended for chronic conditions.
Reports from April 3, 2026, indicate that the trend is particularly prevalent in urban centers such as Hyderabad [1, 2]. Couples are turning to drugs like Mounjaro and Wegovy to secure quick-fix weight loss before their nuptials [1, 2].
The market for these treatments is expanding rapidly. Some estimates suggest India's obesity-drug market could reach $860.34 million by 2030 [1], while other projections place the domestic sales potential at $1 billion [3].
Accessibility to these drugs is shifting as patent protections expire. The patent for semaglutide in India expired on March 20, 2026 [4]. This development is expected to pave the way for generic versions of the drug, potentially lowering costs, and increasing availability for those seeking rapid weight loss.
Availability has already been increasing in recent years. Wegovy was launched in India in 2025 [5]. The combination of available supply and high social demand has integrated these medical injections into the standard pre-wedding beauty regimen for some urban residents [1, 2].
“Urban brides and grooms in India are using injectable GLP-1 weight-loss drugs to prepare for their wedding days.”
The normalization of GLP-1 drugs for cosmetic purposes in India reflects a convergence of pharmaceutical availability and rigid social beauty standards. As patents expire and generic versions enter the market, the barrier to entry for these medications drops, likely increasing the prevalence of off-label use among non-diabetic populations seeking rapid aesthetic transformations.
